Qsymia vs Zepbound: Weight Loss Medication Comparison

Compare Qsymia extended-release capsules and Zepbound injections: distinct mechanisms, placebo-controlled evidence, dosing, tapering, pregnancy risks and access.

Overview: Two Different Weight Loss Approaches

Qsymia’s March 2026 label identifies phentermine/topiramate extended-release capsules, a Schedule IV oral chronic weight-management treatment for eligible adults and adolescents aged 12 or older. It is not an immediate-release combination or a 75%/25% ingredient blend. Its mechanism differs from tirzepatide’s GIP/GLP-1 agonism; that does not establish a twofold efficacy ratio or absence of neurological effects with Zepbound.

The current Mounjaro label covers glycemic control in type 2 diabetes from age 10 and cardiovascular-event risk reduction in adults with type 2 diabetes at high cardiovascular risk. Zepbound contains tirzepatide but has adult weight-management and moderate-to-severe obstructive-sleep-apnea indications in adults with obesity. Approval of one brand does not automatically transfer its indication to another.

Mechanism of Action: Completely Different Approaches

Different pharmacology explains distinct precautions, but not a universal clinical ranking.

Qsymia: Phentermine and Topiramate Extended Release

Qsymia’s March 2026 label identifies phentermine/topiramate extended-release capsules, a Schedule IV oral chronic weight-management treatment for eligible adults and adolescents aged 12 or older. It is not an immediate-release combination or a 75%/25% ingredient blend. Its mechanism differs from tirzepatide’s GIP/GLP-1 agonism; that does not establish a twofold efficacy ratio or absence of neurological effects with Zepbound.

Zepbound: GIP and GLP-1 Receptor Agonism

Semaglutide activates the GLP-1 receptor; tirzepatide activates GIP and GLP-1 receptors. Both can improve glucose regulation and reduce appetite. Dual receptor activity is a mechanistic distinction, not proof of better outcomes for every person or of preserved muscle. This comparison concerns the named weekly injections unless another formulation is specified.

Weight Loss Efficacy: Clinical Trial Results

Separate placebo-controlled programs show meaningful loss with both regimens; they are not a randomized Qsymia-versus-Zepbound comparison.

Qsymia Weight Loss

CONQUER enrolled 2,487 adults with BMI 27–45 and at least two comorbidities. At 56 weeks, intention-to-treat mean loss was 7.8% at phentermine/topiramate 7.5/46 mg and 9.8% at 15/92 mg versus 1.2% with placebo. This Vivus-funded, blinded study is positive evidence for the combination, not a direct comparison against Zepbound or a claim that every patient loses 10–11%.

Zepbound Weight Loss

STEP 1 tested weekly semaglutide 2.4 mg in 1,961 adults without diabetes: mean treatment-policy loss was 14.9% versus 2.4% with placebo at 68 weeks. SURMOUNT-1 tested tirzepatide in 2,539 adults without diabetes: treatment-regimen losses at 72 weeks were 15.0%, 19.5% and 20.9% at 5/10/15 mg versus 3.1% with placebo. These separate trials do not establish a head-to-head difference; the frequently quoted 22.5% uses a different estimand.

Dosing and Administration

The following schedules summarize labels; they do not select an individual treatment or switching regimen.

Qsymia Dosing

The label starts Qsymia 3.75/23 mg daily for 14 days, then 7.5/46 mg. After 12 weeks at that dose, the adult 3% weight-loss threshold (or pediatric BMI threshold) guides escalation through 11.25/69 mg for 14 days to 15/92 mg. After 12 weeks at the highest dose, the 5% response threshold guides stopping. Stopping 15/92 mg requires gradual tapering because abrupt withdrawal can precipitate seizures; a prescriber must plan a switch. Renal/hepatic impairment can lower the maximum.

Zepbound Dosing

Mounjaro starts at 2.5 mg once weekly; increases in 2.5-mg steps require additional glycemic control and at least four weeks at the current dose. Zepbound starts at 2.5 mg weekly for four weeks, then 5 mg; later increases require at least four weeks at the current dose, considering response and tolerability. Adult maximum is 15 mg; Mounjaro’s pediatric maximum is 10 mg. Zepbound weight-management maintenance doses are 5, 10 or 15 mg, whereas its OSA maintenance doses are 10 or 15 mg. A maximum is not a target for everyone.

Side Effects: Different Profiles

Symptoms, monitoring and serious warnings differ across these products.

Qsymia Side Effects (CNS-Related)

Qsymia is contraindicated in pregnancy, glaucoma, hyperthyroidism, recent MAO-inhibitor treatment and relevant hypersensitivity. Its label recommends a negative pregnancy test before treatment and monthly during therapy, effective contraception, and dispensing through its REMS-certified pharmacies. Warnings include fetal harm, mood/suicidal symptoms, cognitive impairment, ocular effects, metabolic acidosis, kidney stones and renal changes. Zepbound has different thyroid contraindications and GI/metabolic warnings; neither has blanket long-term safety for everyone.

Zepbound Side Effects (GI-Related)

Nausea, diarrhea, vomiting, constipation and abdominal symptoms occur with both treatments, commonly during escalation. Separate label pools differ in dose, population and follow-up, so a table of unmatched percentages cannot rank tolerability. SURMOUNT-5 reported mainly mild-to-moderate GI events during escalation; it was not designed to establish a definitive safety winner. Symptoms may improve, persist or require dose changes or stopping.

Both semaglutide and tirzepatide have a boxed rodent thyroid C-cell tumor warning; human relevance is unknown. Personal/family medullary thyroid carcinoma or MEN2, and serious hypersensitivity to the respective product, are formal contraindications. Pancreatitis, gallbladder disease, dehydration-related kidney injury, severe GI effects and aspiration around anesthesia require attention; hypoglycemia risk increases with insulin or sulfonylureas. A rare-event percentage from one study cannot quantify every person’s risk.

Serious Warnings and Product-Specific Risks

Qsymia has cardiovascular, psychiatric, ocular, metabolic and renal considerations; Zepbound has different product warnings. No unmatched event list proves one is safer, and “no CNS effects” is not established for tirzepatide.

Cost and Insurance Coverage

Compare a current itemized quote for the exact product, dose, device and prescription indication. Original estimates of roughly $800–$1,500 monthly for branded injections were historical examples, not current offers. Coverage, deductibles, quantity limits and manufacturer-program eligibility vary; commercial savings cards generally have exclusions and do not guarantee a $25 copay or uninsured access. Medicare/Medicaid decisions depend on the covered indication and applicable rules rather than a blanket exclusion of every use.

Retail Pricing (Without Insurance)

The original $1,200–$1,450 figures for both products were not verified current matched quotes. Do not infer equal cost, twice the value or future generic availability from them.

Insurance Coverage

Choose around the actual treatment goal, approved indication, prior response, risks, available formulations and sustainable access. More average weight loss does not necessarily mean the best option for an individual. Type 2 diabetes, established cardiovascular disease, CKD, obesity or OSA can change which product-specific evidence matters. An arbitrary three-month percentage threshold or cost-first ladder does not settle every decision.

Copay Assistance

Manufacturer assistance and retail discount eligibility are separate from insurance. Verify current ongoing dose and total costs rather than assume $0–$250 copays.

Special Considerations and Contraindications

Use each product’s actual contraindications and warnings rather than class-wide shorthand.

Qsymia Contraindications

Qsymia is contraindicated in pregnancy, glaucoma, hyperthyroidism, recent MAO-inhibitor treatment and relevant hypersensitivity. Its label recommends a negative pregnancy test before treatment and monthly during therapy, effective contraception, and dispensing through its REMS-certified pharmacies. Warnings include fetal harm, mood/suicidal symptoms, cognitive impairment, ocular effects, metabolic acidosis, kidney stones and renal changes. Zepbound has different thyroid contraindications and GI/metabolic warnings; neither has blanket long-term safety for everyone.

Zepbound Considerations

Both semaglutide and tirzepatide have a boxed rodent thyroid C-cell tumor warning; human relevance is unknown. Personal/family medullary thyroid carcinoma or MEN2, and serious hypersensitivity to the respective product, are formal contraindications. Pancreatitis, gallbladder disease, dehydration-related kidney injury, severe GI effects and aspiration around anesthesia require attention; hypoglycemia risk increases with insulin or sulfonylureas. A rare-event percentage from one study cannot quantify every person’s risk.

Severe or persistent abdominal pain, repeated vomiting with inability to retain fluids, marked dehydration or a serious allergic reaction needs prompt assessment. Suspected pancreatitis calls for stopping the drug and evaluation; severe allergic symptoms require urgent care. Significant gastroparesis, retinopathy, pregnancy plans and other medicines affect selection. Semaglutide labels advise stopping at least two months before a planned pregnancy; tirzepatide has a separate four-week oral-hormonal-contraception precaution after initiation and each escalation.

For tirzepatide, oral hormonal contraceptive users need a nonoral method or additional barrier protection for four weeks after initiation and after each dose escalation, per label. Pregnancy recognition calls for discontinuation and clinical contact; it is not a “relative contraindication” ranking.

Quick Comparison Table

Which Should You Choose?

Choose around the actual treatment goal, approved indication, prior response, risks, available formulations and sustainable access. More average weight loss does not necessarily mean the best option for an individual. Type 2 diabetes, established cardiovascular disease, CKD, obesity or OSA can change which product-specific evidence matters. An arbitrary three-month percentage threshold or cost-first ladder does not settle every decision.

Choose Qsymia If:

Qsymia can be considered when its indication, preference, contraindications and monitoring requirements fit; it is not merely an older fallback.

Choose Zepbound If:

The current Mounjaro label covers glycemic control in type 2 diabetes from age 10 and cardiovascular-event risk reduction in adults with type 2 diabetes at high cardiovascular risk. Zepbound contains tirzepatide but has adult weight-management and moderate-to-severe obstructive-sleep-apnea indications in adults with obesity. Approval of one brand does not automatically transfer its indication to another.

Choose around the actual treatment goal, approved indication, prior response, risks, available formulations and sustainable access. More average weight loss does not necessarily mean the best option for an individual. Type 2 diabetes, established cardiovascular disease, CKD, obesity or OSA can change which product-specific evidence matters. An arbitrary three-month percentage threshold or cost-first ladder does not settle every decision.

The calculator illustrates arithmetic, not a prescribing algorithm or proof most clinicians prefer one medicine first-line.

Related reading: tirzepatide dosage calculator.